Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-09-20
2005-09-20
Borin, Michael (Department: 1631)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C514S013800
Reexamination Certificate
active
06946439
ABSTRACT:
Compositions and methods effective in inhibiting abnormal or undesirable cell proliferation, particularly endothelial cell proliferation and angiogenesis related to neovascularization and tumor growth are provided. The compositions comprise a naturally occurring or synthetic protein, peptide, or protein fragment containing all or an active portion of the C-terminal portion of proteinase inhibitors such as TFPI. The methods involve administering to a human or animal the composition described herein in a dosage sufficient to inhibit cell proliferation, particularly endothelial cell proliferation. The methods are useful for treating diseases and processes mediated by undesired and uncontrolled cell proliferation, such as cancer, particularly by inhibiting angiogenesis. Administration of the composition to a human or animal having prevascularized, metastasized tumors is useful for preventing the growth or expansion of such tumors.
REFERENCES:
patent: 4552888 (1985-11-01), Koppel et al.
patent: 4994443 (1991-02-01), Folkman et al.
patent: 5001116 (1991-03-01), Folkman et al.
patent: 5021404 (1991-06-01), Folkman et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5358959 (1994-10-01), Halperin et al.
patent: 5385885 (1995-01-01), Gasic et al.
patent: 5589359 (1996-12-01), Innis et al.
patent: 5653744 (1997-08-01), Khouri
patent: 5770563 (1998-06-01), Roberts et al.
patent: 5795865 (1998-08-01), Markland et al.
patent: 5981471 (1999-11-01), Papathanassiu et al.
patent: 6010880 (2000-01-01), Markland et al.
patent: WO 97/35609 (1997-02-01), None
patent: WO 97/09063 (1997-03-01), None
Algire, G.H. et al., Vascular reactions of normal and malignant tumors in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants,Journal of the National Cancer InstituteVol/Iss: 6, pp. 73-85, Aug. 1945.
Bok, R.A. et al., Quantiative Characterization of the Binding of Plasminogen to Intact Fibrin Clots, Lysine-Sepharose, and Fibrin Cleaved by Plasmin,Biochemistry, Vol/Iss: 24, pp. 3279-3286, 1985.
Brem, H. et al., Title: Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas,Journal of Neurosurgery, Vol/Iss: 74, pp. 441-446, Mar. 1, 1991.
Broze et al., Regulation of Coagulation by a Multivalent Kunitz-Type Inhibitor,Biochemistry, Vol/Iss: 29(33), pp. 7539-7546, Aug. 21, 1990.
Broze, G.J., Jr. et al., Tissue Factor Pathway Inhibitor and the Revised Theory of Coagulation,Annu. Rev. Med., Vol/Iss: 46, pp.: 103-112, 1995.
Cao, Y. et al., gro-B, a-C-X-C-Chemokine, is an Angiogenesis Inhibitor that Suppresses the Growth of Lewis Lung Carninoma in Mice,Journal of Experimental Medicine, Vol/Iss: 182, pp. 2069-2077, Dec. 1, 1995.
Cao, Y. et al., Kringle Domains of Human Angiostatin,The Journal of Biological Chemistry, Vol/Iss: 271(46), pp. 29461-29467, Nov. 15, 1996.
Cardiff, R.D., Protoneoplasia: The Molecular Biology of Murine Mammary Hyperplasia (Abstract only),Advances in Cancer Research, Vol/Iss: 42, pp. 167-190, Jan. 1, 1984.
Chen, C. et al., Title: A Strategy to Discover Circulating Angiogenesis Inhibitors Generated by Human Tumors,Cancer Research, Vol/Iss: 55, pp. 4230-4233, Oct. 1, 1995.
Clements et al., Title: Kallikreins and kinins in inflammatory-like events in the reproductive tract (Abstract only),Pharmacological Research, Vol/Iss: 35(6), pp. 537-540, Jun. 1997.
Contrino, J., In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease,Nature Medicine, Vol/Iss: 2(2), pp. 209-215, Feb. 1996.
Crum, R. et al., Title: A New Class of Steroids Inhibits Angiogenesis in the Presence of Heparin or a Heparin Fragment,Science, Vol/Iss: 230, pp. 1375-1378, Dec. 20, 1985.
Davies et al., Title: Pathobiology of Intimal Hyperplasia,British Journal of Surgery, Vol/Iss: 81(4), pp. 1254-1269, Sep. 1994.
Devaraj et al., Title: The effects of alpha-tocopherol on critical cells in atherogenesis,Current Opinion in Lipidology, Vol/Iss: 9(1), pp. 11-15, Feb. 1998.
Dinbergs et al., Cellular Response to Transforming Growth Factor-β1 and Basic Fibroblast Growth Factor Depends on Release Kinetics and Extracellular Matrix Interactions,The Journal of Biological Chemistry, Vol/Iss: 271(47), pp. 29822-29829, Nov. 22, 1996.
Enjyoji, K. et al., Effect of Heparin on the Inhibition of Factor Xa by Tissue Factor Pathway Inhibitor: A Segment, Gly212—Phe243, of the third Kunitz Domain is a Heparin-Binding Site,Biochemistry, Vol/Iss: 34(17), pp. 5725-5735, 1995.
Ferenczy, A. et al., The cytodynamics of endometrial hyperplasia and carcinoma,Annales de Pathologie, Vol/Iss: 3(3), pp. 189-201, Sep. 1983.
Folkman, J., Tumor angiogenesis and tissue factor,Nature Medicine, Vol/Iss: 2, pp. 167-168, Feb, 1, 1996.
Folkman, J., What is the Evidence that Tumors are Angiogenesis Dependent?,Journal of the National Cancer Institute, Vol/Iss: 82, pp. 4-6, Jan. 3, 1990.
Folkman, J., Angiogenesis in cancer, vascular, rheumatoid and other disease,Nature Medicine, Vol/Iss:1(1), pp. 27-31, Nov. 1, 1995.
Folkman, J., Angiogenesis and Its Inhibitors,Important Advances in Oncology, Vol/Iss: , pp. 42-62, 1985.
Folkman, J., Tumor Angiogenesis: Therapeutic Implications,New England Journal of Medicine, Vol/Iss: 285 (21), pp. 1182-1186, Nov. 18, 1971.
Folkman, J. et al., Long-term culture of capillary endothelial cells,Proceedings of the National Academy of Science USA, Vol/Iss: 76, pp. 5217-5221, Oct. 1, 1979.
Folkman, J. et al., Induction of angiogenesis during the transition from hyperplasia to neoplasia,Nature, Vol/Iss: 339, pp. 58-61, May 4, 1989.
Folkman, J. et al., Tumor Behavior in Isolated Perfused Organs in vitro Growth and Metastases of Biopsy Material in Rabbit Thyroid and Canine Intestinal Segment,Annals of Surgery, Vol/Iss: 164(3), pp. 491-502, Sep. 1, 1966.
Gimbrone, M.A. et al., Tumor growth and neovascularization: An experimental model using the rabbit cornea,Journal of the National Cancer Institute, Vol/Iss: 52(2), pp. 413-427: Feb. 1974.
Gimbrone, M.A. et al., Tumor dormancy in vivo by Prevention of Neovascularization,Journal of Experimental Medicine, Vol/Iss: 136, pp. 261-276, 1972.
Good, D.J. et al., A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thombospondin,Proceedings of the National Academy of Science USA, Vol/Iss: 87, pp. 6624-6628, Sep. 1990.
Gross, J.L. et al., Modulation of Solid Tumor Growth in vivo by bFGF (Abstract only),Proceedings of the American Association of Cancer Research, Vol/Iss: 31, pp. 79, Mar. 1990.
Gupta, S. et al., A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4,Proceedings of the National Academy of Science USA, Vol/Iss: 92, pp. 7799-7803, Aug. 1995.
Haas, A.F. et al., Angiolymphoid Hyperplasia with Eosinophila of the Hand,Journal of Dermatologic Surgery and Oncology, Vol/Iss: 17, pp. 731-734, Sep. 1991.
Hanada et al., Carboxyl Terminal Basic Amino Acid Region of TFPI Prevents Proliferation of Human Smooth Muscle Cells by Inhibiting Activation of Map Kinase Kinase ( Abstract only),Thrombosis and Haemostatis, Supplement, Jul. 2001.
Holmgren, L. et al., Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression,Nature Medicine, Vol/Iss: 1(2), pp. 149-153, Feb. 1995.
Homandberg, G.A. et al., Heparin-binding Fragments of Fibronectin are Potent Inhibitors of Endothelial Cell Growth,American Journal of Pathology, Vol/Iss: 120, pp. 327-332, Sep. 1985.
Ingber, D. et al., Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth,Nature, Vol/Iss: 348, pp. 555-557, Dec. 6, 1990.
Ishino et al., An Autopsy Case of Cerebral Form of v. Winlwarter-Buerger's Disease with a Chronic Course of 12 Years,Folia Psychiatrica Neurologica Japonica, Vol/Iss: 27(3), pp. 207-221, 1973.
Kamikubo, Y. et al., Human Recombinant Tissue-Factor Pathway Inhibitor Prevents the Proliferation of Cultured Human Neonatal Aortic Smooth Muscle Cells,FEBS Letters, Vol/Iss: 407
Green Shawn J.
Hembrough Todd
Papathanassiu Adonia E.
Pribluda Victor P.
Borin Michael
Entre Med, Inc.
Kilpatrick & Stockton LLP
LandOfFree
Compositions and methods for inhibiting cellular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for inhibiting cellular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for inhibiting cellular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3423475